MERCK Press Releases http://www.thailand4.com/merck/ Merck Awarded Australian CRISPR Nickase Patent for Foundational Genome-Editing Technology - Patent covers paired Cas9 nickase technology to reduce off-target effects, advance gene therapy and research - Expands company's foundational CRISPR cutting and integration IP necessary to correct genetic defects in gene therapy patients - Merck to th-TH Fri, 21 Sep 2018 5:36:03 +0700 Merck Receives Recommendation for Approval in 21 EU Countries for the New Formulation of Euthyrox(R) http://www.thailand4.com/.food/2018-07-26/0784b5f8b28ee583dfdb87bbf063e227/ - German Federal Institute for Drugs and Medical Devices (BfArM) recommends new formulation of Euthyrox(R) for approval in 21 EU countries - BfArM is acting as a representative of all 21 EU countries involved in the EU worksharing procedure Merck, a http://www.thailand4.com/.food/2018-07-26/0784b5f8b28ee583dfdb87bbf063e227/ Thu, 26 Jul 2018 14:00:00 +0700 Merck Launches Online Platform Fertility.com http://www.thailand4.com/.food/2018-07-03/479eebaf0a91086bb2436bb0511f6138/ - Offering the latest scientific information to healthcare professionals in the advancing field of fertility - Supporting women, men and couples who are looking for information about fertility and/or undergoing fertility treatment (Photo: http://www.thailand4.com/.food/2018-07-03/479eebaf0a91086bb2436bb0511f6138/ Tue, 03 Jul 2018 15:15:56 +0700 Merck Launches Two New Technologies for Improved Efficiency in Fertility Labs http://www.thailand4.com/.food/2018-07-03/f8494ca8dac48c46bfebdc22c356437d/ - QBOX IVF streamlines data transfer between lab instruments and Electronic Medical Record providers - Geri(R) Assess 2.0 enables automatic detection of key events in embryo and blastocyst development, improving efficiencies in assessment - Merck http://www.thailand4.com/.food/2018-07-03/f8494ca8dac48c46bfebdc22c356437d/ Tue, 03 Jul 2018 8:12:15 +0700 Merck Drives Thought Leadership in Ethical Gene Editing http://www.thailand4.com/.it/2018-06-13/36b8207bfc7f13bbda7675004e727c9b/ - Co-authored publication, Ethical Considerations in the Manufacture, Sale and Distribution of Genome-Editing Technologies, accepted in leading bioethics journal - Highlights importance of science-based bioethics in genome editing and novel processes http://www.thailand4.com/.it/2018-06-13/36b8207bfc7f13bbda7675004e727c9b/ Wed, 13 Jun 2018 9:32:17 +0700 Merck Brings Biotechs Closer to Drug Therapy Production and Commercialization http://www.thailand4.com/.it/2018-06-06/7dc5a90415e37d83000df9cba0bfe123/ - Opens North America#s first BioReliance(R) End-to-End Biodevelopment Center to help customers with biopharmaceutical manufacturing processes - Accelerates clinical development from DNA to market - Advance Biotech Grant Program expands global http://www.thailand4.com/.it/2018-06-06/7dc5a90415e37d83000df9cba0bfe123/ Wed, 06 Jun 2018 8:37:33 +0700 Two Year Update of Pivotal JAVELIN Merkel 200 Trial Shows Continued Durable Responses with BAVENCIO(R) (avelumab) http://www.thailand4.com/.food/2018-06-05/85364bd819e7235f135f4c5b046d8e8d/ - Two-year follow-up data on meaningful durable response, overall survival (OS) and progression-free survival (PFS) to be presented in patients with metastatic Merkel cell carcinoma (mMCC), a rare and aggressive type of skin cancer Merck and Pfizer http://www.thailand4.com/.food/2018-06-05/85364bd819e7235f135f4c5b046d8e8d/ Tue, 05 Jun 2018 8:00:49 +0700 Merck Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018 http://www.thailand4.com/.food/2018-06-05/a0355552fab4008099c8d913e0fc5f39/ M7824 (TGF-ss trap/anti-PD-L1): 3007, 9017, 2566, Tepotinib (c-Met kinase inhibitor): 9082, M2698 (dual p70S6k/Akt inhibitor): M6620 (ATR inhibitor): M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - M7824 is an http://www.thailand4.com/.food/2018-06-05/a0355552fab4008099c8d913e0fc5f39/ Tue, 05 Jun 2018 8:00:38 +0700 Merck Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018 http://www.thailand4.com/.food/2018-06-04/852d81fb89c626df5db3fb888f1047c4/ Tepotinib (c-Met kinase inhibitor): 9082, M7824 (TGF-ss trap/anti-PD-L1): 3007, 9017, M2698 (dual p70S6k/Akt inhibitor): M6620 (ATR inhibitor): M3814 (DNA-PK): 2518 Not intended for UK- or US-based media - Data from an ongoing http://www.thailand4.com/.food/2018-06-04/852d81fb89c626df5db3fb888f1047c4/ Mon, 04 Jun 2018 8:54:34 +0700 Merck to Use Genome Editing in Study of Gut Bacteria to Benefit Malnourished Children http://www.thailand4.com/.food/2018-05-17/08f3be27a24b766f3f4e699056d2926d/ - Collaboration with Washington University on gut bacteria research could lead to diagnostics, treatment for malnourished children - Study to use Merck#s genome-editing technology Merck , a leading science and technology company and leader in genome http://www.thailand4.com/.food/2018-05-17/08f3be27a24b766f3f4e699056d2926d/ Thu, 17 May 2018 8:00:30 +0700 เมอร์ค ใช้เทคโนโลยีการปรับแต่งจีโนมในการศึกษาแบคทีเรียในลำไส้ เพื่อช่วยเหลือเด็กขาดสารอาหาร http://www.thailand4.com/food/2018-05-17/b2271f68863d4d8ed0c6bc1d37d5e472/ - ความร่วมมือกับมหาวิทยาลัยวอชิงตันเกี่ยวกับการวิจัยแบคทีเรียในลำไส้ อาจนำไปสู่การวินิจฉัยและรักษาเด็กที่ขาดสารอาหาร - การศึกษาดังกล่าวจะใช้เทคโนโลยีการปรับแต่งจีโนมของเมอร์ค เมอร์ค ( Merck ) บริษัทวิทยาศาสตร์และเทคโนโลยีชั้นแนวหน้า http://www.thailand4.com/food/2018-05-17/b2271f68863d4d8ed0c6bc1d37d5e472/ Thu, 17 May 2018 8:00:37 +0700 Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline http://www.thailand4.com/.food/2018-05-17/1ff578148bde7a62b42a2996d2e0dedf/ ASCO Abstract # ERBITUX(R) (cetuximab): 3521, 3534, avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, tepotinib (c-Met kinase inhibitor): 9082, M6620 (ATR inhibitor): 2549, M3814 http://www.thailand4.com/.food/2018-05-17/1ff578148bde7a62b42a2996d2e0dedf/ Thu, 17 May 2018 10:43:58 +0700 http://www.thailand4.com/ http://www.thailand4.com/ Thu, 01 Jan 1970 7:00:00 +0700 Merck Receives Patent for CRISPR Technology in China http://www.thailand4.com/.food/2018-04-24/5773bb4d505b30da5c61c7dbf117e7d4/ - Patent in China covers integration of an external DNA sequence into the chromosome of eukaryotic cells - Company to license CRISPR-related patents to interested parties, supports genome-editing research under ethical and legal standards - http://www.thailand4.com/.food/2018-04-24/5773bb4d505b30da5c61c7dbf117e7d4/ Tue, 24 Apr 2018 8:46:53 +0700 Merck Helps Accelerate Global Access to Affordable Vaccines http://www.thailand4.com/.gen/2018-04-17/5bb9879c2668808420fb45e1b1947ab9/ - Collaboration with Oxford University to develop cost-effective vaccine manufacturing processes, accelerate vaccine availability - New vaccine manufacturing facility in Ghana to serve as a catalyst to help country and region address health http://www.thailand4.com/.gen/2018-04-17/5bb9879c2668808420fb45e1b1947ab9/ Tue, 17 Apr 2018 7:18:28 +0700 เมอร์ค เดินหน้าสนับสนุนการผลิตวัคซีนราคาไม่แพง หวังให้ทั่วโลกเข้าถึงได้ง่ายขึ้น http://www.thailand4.com/gen/2018-04-17/b2cd21c34eb9aa3cb39bf932aa999a79/ - ร่วมมือกับมหาวิทยาลัยออกซ์ฟอร์ดพัฒนากระบวนการผลิตวัคซีนที่ใช้ต้นทุนไม่สูง ช่วยให้ผลิตวัคซีนได้มากขึ้น - วางแผนสร้างโรงงานผลิตวัคซีนแห่งใหม่ในประเทศกานา เพื่อช่วยให้ทวีปแอฟริกาสามารถรับมือกับความท้าทายด้านสุขภาพได้ดีขึ้น เมอร์ค ( Merck ) http://www.thailand4.com/gen/2018-04-17/b2cd21c34eb9aa3cb39bf932aa999a79/ Tue, 17 Apr 2018 7:18:30 +0700 Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan http://www.thailand4.com/.food/2018-03-28/fece531bd3d925965185035f768d03a8/ - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck#s investigational highly selective c-Met receptor tyrosine kinase inhibitor - First regulatory designation for tepotinib - SAKIGAKE designation encompasses http://www.thailand4.com/.food/2018-03-28/fece531bd3d925965185035f768d03a8/ Wed, 28 Mar 2018 8:15:44 +0700 เมอร์ค ทุ่มงบ 40 ล้านยูโร ยกระดับการผลิตและการกระจายสินค้าในเอเชีย http://www.thailand4.com/it/2018-02-21/01d3486e89739a2b338d9067518144e3/ - เร่งเปิดศูนย์ผลิตอุปกรณ์แบบใช้ครั้งเดียว Mobius(R) เพื่อรองรับการพัฒนายาชีววัตถุคล้ายคลึงในจีน เมอร์ค ( Merck ) บริษัทวิทยาศาสตร์และเทคโนโลยีชั้นนำ ประกาศทุ่มเงินลงทุนเพิ่มเติมอีก 40 ล้านยูโร เพื่อสร้างศูนย์การผลิตและกระจายสินค้าในเอเชียในช่วง 2 http://www.thailand4.com/it/2018-02-21/01d3486e89739a2b338d9067518144e3/ Wed, 21 Feb 2018 11:17:02 +0700 Merck Invests Additional EUR40 Million to Enhance Manufacturing and Distribution in Asia http://www.thailand4.com/.it/2018-02-21/6eb5696bf8cd099f6252bf011519186b/ - Builds capabilities with two new manufacturing and distribution centres in South Korea and India - Accelerates Mobius(R) single-use manufacturing in China for biosimilars development Merck , a leading science and technology company, today announced http://www.thailand4.com/.it/2018-02-21/6eb5696bf8cd099f6252bf011519186b/ Wed, 21 Feb 2018 11:16:59 +0700 Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer http://www.thailand4.com/.food/2018-02-16/1a1df6eac0d63c1510b235e6fe4eea1e/ Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after http://www.thailand4.com/.food/2018-02-16/1a1df6eac0d63c1510b235e6fe4eea1e/ Fri, 16 Feb 2018 8:23:13 +0700 The Consumer Health of Merck Walks the Talk with its WE100 Movement http://www.thailand4.com/.food/2018-01-18/fc4635cfd4c27ce1f06eb4665356aa74/ - Consumer Health accelerates its WE100(R) movement by launching new partnership programme with pharmacists in the UK on enabling 100 years of healthy living - Femibion(R) celebrates working mums with new MumPlus campaign - Expansion of Vitamin D brand http://www.thailand4.com/.food/2018-01-18/fc4635cfd4c27ce1f06eb4665356aa74/ Thu, 18 Jan 2018 16:00:09 +0700 FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA(R) in Advanced Renal Cell Carcinoma http://www.thailand4.com/.food/2017-12-22/a768bd327c930c076b4f3cf100db9d25/ - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III first-line study Merck and Pfizer Inc. (NYSE: PFE) today announced http://www.thailand4.com/.food/2017-12-22/a768bd327c930c076b4f3cf100db9d25/ Fri, 22 Dec 2017 8:26:54 +0700 Merck Signs Commercial Supply Agreement with bluebird bio for Viral Vector Manufacturing http://www.thailand4.com/.food/2017-12-21/504add7e14779119fe6d9fe43a23de35/ - Underscores the Life Science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy Merck , a leading science and technology company, today announced that it has signed a commercial http://www.thailand4.com/.food/2017-12-21/504add7e14779119fe6d9fe43a23de35/ Thu, 21 Dec 2017 8:01:15 +0700 เมอร์ค ลงนามข้อตกลงผลิต Viral Vector ให้ บลูเบิร์ด ไบโอ http://www.thailand4.com/food/2017-12-21/86c2e2155adb7f0abaeb5f41527a3dd5/ - ตอกย้ำสถานะของธุรกิจชีววิทยาศาสตร์ของเมอร์ค ในฐานะผู้ผลิตตามสัญญาจ้างและผู้จัดหา Viral Vector เพื่อการพาณิชย์สำหรับทำยีนบำบัดชั้นนำของวงการ เมอร์ค ( Merck ) บริษัทวิทยาศาสตร์และเทคโนโลยีชั้นนำ ได้ลงนามข้อตกลงผลิต Viral Vector (พาหะที่เป็นไวรัส) http://www.thailand4.com/food/2017-12-21/86c2e2155adb7f0abaeb5f41527a3dd5/ Thu, 21 Dec 2017 8:01:18 +0700 Singapore#s IP Office to Grant Merck#s Patent Application for CRISPR Technology http://www.thailand4.com/.food/2017-12-20/d0244ed2303463649a3ffa0a84cd605c/ - Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Fourth patent allowance for Merck#s CRISPR similar patents from Australian, Canadian and European Patent Offices http://www.thailand4.com/.food/2017-12-20/d0244ed2303463649a3ffa0a84cd605c/ Wed, 20 Dec 2017 8:05:38 +0700 เมอร์ค ลงนามในข้อตกลงการจัดจำหน่ายกับ Avanti(R) Polar Lipids http://www.thailand4.com/food/2017-12-12/e73bc401ddebba7cecd40bd59105935b/ เมอร์ค ( Merck ) บริษัทวิทยาศาสตร์และเทคโนโลยีชั้นนำ ประกาศในวันนี้ว่า บริษัทได้บรรลุข้อตกลงร่วมกับ Avanti(R) Polar Lipids ในการเป็นผู้จัดจำหน่ายระหว่างประเทศแต่เพียงผู้เดียว http://www.thailand4.com/food/2017-12-12/e73bc401ddebba7cecd40bd59105935b/ Tue, 12 Dec 2017 13:57:36 +0700 Merck Signs Distribution Agreement with Avanti(R) Polar Lipids http://www.thailand4.com/.food/2017-12-12/383556b53b49905cb8936c53b289b464/ Merck , a leading science and technology company, today announced that it has entered into an agreement with Avanti(R) Polar Lipids to be the exclusive multinational distributor of the USA-based company#s research lipids portfolio outside of the United http://www.thailand4.com/.food/2017-12-12/383556b53b49905cb8936c53b289b464/ Tue, 12 Dec 2017 13:57:32 +0700 Merck Announces FDA 510(k) Clearance of Partner Genea Biomedx#s Fertility Benchtop Incubator Geri(TM) http://www.thailand4.com/.food/2017-12-06/283fed7b0e85f8c55a69766cb8ee030c/ - Expanded Fertility Technology portfolio highlights Merck#s commitment to improve fertility treatment outcomes for patients - U.S. commercial availability expected in first half of 2018 Merck, a leading science and technology company, today announced http://www.thailand4.com/.food/2017-12-06/283fed7b0e85f8c55a69766cb8ee030c/ Wed, 06 Dec 2017 9:49:30 +0700 Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer http://www.thailand4.com/.food/2017-11-29/fcc9d8bd459ab8a5a51d8d0e084ce808/ - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival compared to http://www.thailand4.com/.food/2017-11-29/fcc9d8bd459ab8a5a51d8d0e084ce808/ Wed, 29 Nov 2017 9:26:39 +0700